Patierno, Barrett Take to National Stage on Disparities
Published
From the Duke Cancer Institute archives. Content may be out of date.
2022 AACR Cancer Disparities Progress Report Released
The American Association for Cancer Research (AACR) held a Virtual Congressional Briefing on June 8 to release the AACR Cancer Disparities Progress Report 2022.
The goal of this report is "to increase public awareness and understanding of cancer health disparities, highlight areas of recent progress in reducing cancer health disparities and provide specific recommendations for achieving health equity."
The report was developed by preeminent cancer disparities researchers, including deputy director of Duke Cancer Institute Steven Patierno, PhD. The briefing on June 8 featured Congresswoman Brenda Lawrence (D-MI) and Senator Shelley Moore Capito (R-WV) and included testimonies and a LIVE panel discussion with leading cancer disparities researchers, including Patierno, as well as survivors of cancer whose stories are included in the report.
ASCO-ACCC Issues Joint Statement on Increasing Racial and Ethnic Diversity in Cancer Clinical Trials
Nadine Barrett, PhD,director of the Duke CTSI Center for Equity in Research and associate director, Equity, Community and Stakeholder Strategy, DCI COEE, is a co-author of a joint statement from leading cancer organizations outlining their recommendations for expanding diversity in cancer clinical trials that include access, equity focused design, stakeholder partnerships, education and training, EDI (equity, diversity and inclusion) investment, and sharing data & strategies.
Duke Cancer Institute is one of 75 sites nationwide to help develop the recommendations.
Gayathri Devi, PhD, MS, is the recipient of this year’s Award for Addressing Health Equity Through Partnership and Innovation from the Association for Clinical and Translational Science (ACTS).“These award winners and their work represent the values and mission of ACTS for innovation, team science and community involvement applying principles of translational science,” said ACTS President Allan R. Brasier, MD.Devi received the award this week in the iconic International Ballroom of the historic Washington Hilton during the Translational Science 2025 meeting in Washington, D.C. The award recognizes investigators who translate their findings from bench to bedside to curbside."The Translational Science meeting is vital to the community because it provides opportunities to engage and learn about innovative, collaborative approaches to research, like those of Dr. Devi, which seek to improve health outcomes,” said ACTS Executive Director Kim Stelmaszak, CAE.Devi is a professor of surgery at the Duke School of Medicine and the program leader of the Duke Consortium for Inflammatory Breast Cancer. She received this award in recognition of the work conducted by the Rare 2 Care team. Rare 2 Care is a multidisciplinary, global partnership to develop innovative disease models, therapeutic strategies and community engaged research with providers and advocates to dismantle barriers to health care for patients with rare cancers.“Our team has made significant strides in addressing rare breast cancer care and health disparities, particularly in aggressive subtypes like triple-negative breast cancer and inflammatory breast cancer,” Devi said. “The initiative that started in 2015 has grown into a multifaceted rare cancer collective driven by the "Bench to Bedside to Curbside and Back" ethos, integrating clinical and laboratory findings with community-driven research. This holistic strategy ensures that scientific discoveries have real-world applications that benefit both patients and the broader community.”
Gayathri Devi, PhD, MS, is the recipient of this year’s Award for Addressing Health Equity Through Partnership and Innovation from the Association for Clinical and Translational Science (ACTS).“These award winners and their work represent the values and mission of ACTS for innovation, team science and community involvement applying principles of translational science,” said ACTS President Allan R. Brasier, MD.Devi received the award this week in the iconic International Ballroom of the historic Washington Hilton during the Translational Science 2025 meeting in Washington, D.C. The award recognizes investigators who translate their findings from bench to bedside to curbside."The Translational Science meeting is vital to the community because it provides opportunities to engage and learn about innovative, collaborative approaches to research, like those of Dr. Devi, which seek to improve health outcomes,” said ACTS Executive Director Kim Stelmaszak, CAE.Devi is a professor of surgery at the Duke School of Medicine and the program leader of the Duke Consortium for Inflammatory Breast Cancer. She received this award in recognition of the work conducted by the Rare 2 Care team. Rare 2 Care is a multidisciplinary, global partnership to develop innovative disease models, therapeutic strategies and community engaged research with providers and advocates to dismantle barriers to health care for patients with rare cancers.“Our team has made significant strides in addressing rare breast cancer care and health disparities, particularly in aggressive subtypes like triple-negative breast cancer and inflammatory breast cancer,” Devi said. “The initiative that started in 2015 has grown into a multifaceted rare cancer collective driven by the "Bench to Bedside to Curbside and Back" ethos, integrating clinical and laboratory findings with community-driven research. This holistic strategy ensures that scientific discoveries have real-world applications that benefit both patients and the broader community.”
